Ad5-nCoV

AXP000169.2 · Vaccine

Platform
human adenovirus 5 (non-replicating)
Targets
SARS-CoV-2 S
Originator
Beijing Institute of Biotechnology (Academy of Military Medical Sciences)
Sponsor
CanSino Biologics

Names

NameTypeSource
Ad5-nCoVpreferred name, codecurator, wikidata
Convideciabrandwikidata
Convidecia Airbrandwikidata
PakVac ambiguousbrandwikidata

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
replication-defective adenovirus type 5 encoding the SARS-CoV-2 spike
Transgenes
SARS-CoV-2 spike
Route
intramuscular, inhaled
Source
evidence

Cross-references

Wikidata
Q96695265
FDA UNII
5AHC3V2UQS

Approvals

AgencyRegionDateStatusBrandIndicationSource
NMPACN2020-06-25conditionalConvideciaLimited use in the Chinese militarysource
NMPACN2021-02conditionalConvideciaPrevention of COVID-19, general usesource
otherXW2022-05conditionalConvideciaWHO emergency use listingsource
NMPACN2022-09-04conditionalConvidecia AirInhaled booster dose against COVID-19source

Clinical trials (18)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05886790A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical RoutesUnknown2023-05-302023-12-31450COVID-19
NCT05855408Effectiveness of a Second COVID-19 Vaccine Booster in Chinese AdultsUnknownPhase 42023-05-182024-05-1810000COVID-19
NCT05680896SARS-CoV-2 Infection Among Healthcare WorkersUnknown2023-02-012023-03-21600COVID-19
NCT05517642IH Convidecia as Second Booster Dose Against Breakthrough InfectionsCompletedPhase 32022-09-202023-05-02540COVID-19
NCT05303584Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 VaccineCompletedPhase 42022-04-232022-06-20362COVID-19
NCT05169008A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and AdolescentsTerminatedPhase 32022-02-252023-01-1391COVID-19
NCT05204589Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 VaccineCompletedPhase 32022-01-222022-04-0110285COVID-19
NCT05124561Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)WithdrawnPhase 32021-12-152022-04-150COVID-19
NCT05293223Phase IIB Study of Recombinant Novel Coronavirus VaccineCompletedPhase 22021-10-012022-11-1588COVID-19 Vaccine
NCT04952727Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly AdultsCompletedPhase 42021-08-262021-11-26300COVID-19
NCT05043259Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 VaccineCompletedPhase 1/22021-08-142021-11-01423COVID-19
NCT05005156Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIVCompletedPhase 22021-06-242023-01-13155Covid19
NCT04916886A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.Completed2021-06-032022-07-312021COVID-19
NCT04892459Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)CompletedPhase 42021-05-252021-07-25300COVID-19
NCT04833101Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit VaccineCompletedPhase 42021-04-072021-09-18120COVID-19
NCT05313646Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy AdultsCompletedPhase 42021-03-082021-04-081050COVID-19
NCT04552366A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy AdultsCompletedPhase 12020-09-292020-12-31149COVID-19
NCT04341389A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)CompletedPhase 22020-04-122020-11-30508COVID-19

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41569047Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously.Human vaccines & immunotherapeutics2026name in title: Ad5-nCoV
PMID 41785679Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.Vaccine2026name in abstract: Ad5-nCoV
PMID 41863180Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.Vaccine2026name in abstract: Ad5-nCoV
PMID 42464341Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination.Journal of translational medicine2026cited by trial NCT04892459
PMID 43013717Effects of COVID-19 vaccination type and vaccination-infection interval on viral clearance dynamics in Omicron BA.5 patients at Guangzhou Fangcang shelter hospitals: A propensity score matched multicenter retrospective cohort study.Human vaccines & immunotherapeutics2026name in abstract: Ad5-nCoV
PMID 39765039Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases.Archives of medical research2025name in abstract: Ad5-nCoV
PMID 39935878Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.Frontiers in public health2025name in abstract: Convidecia
PMID 40140382Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China.Nature communications2025name in abstract: Ad5-nCoV
PMID 40498774Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH).PloS one2025cited by trial NCT05005156
PMID 40775215Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.Nature communications2025cited by trial NCT05886790
PMID 41103414Impact of an aerosolized or intramuscular adenovirus type 5-vectored COVID-19 vaccine on Fc-mediated immune effector functions in a hybrid immunity population.Frontiers in immunology2025name in abstract: Ad5-nCoV
PMID 37933089Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.Emerging microbes & infections2024name in abstract: Ad5-nCoV
PMID 38219181Heterologous COVID-19 vaccines intervention effect on reactogenicity.JPMA. The Journal of the Pakistan Medical Association2024name in abstract: Ad5-nCoV
PMID 38456703SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients.mBio2024cited by trial NCT05680896
PMID 39482336Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.NPJ vaccines2024cited by trial NCT05517642
PMID 36503413Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.Emerging microbes & infections2023cited by trial NCT05043259
PMID 36888640Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.PloS one2023name in abstract: Ad5-nCoV
PMID 36898400Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.The Lancet. Respiratory medicine2023cited by trial NCT05303584
PMID 37202147Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials.The Journal of infectious diseases2023cited by trial NCT05303584
PMID 37209700Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.The Lancet. Respiratory medicine2023name in title: Ad5-nCoV
PMID 37352880Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.The Lancet. Infectious diseases2023cited by trial NCT05204589
PMID 37360864Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.The Lancet regional health. Western Pacific2023cited by trial NCT04952727
PMID 37428653Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19.Human vaccines & immunotherapeutics2023cited by trial NCT04341389
PMID 37432025Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.Expert review of vaccines2023cited by trial NCT04916886
PMID 37449956Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.Human vaccines & immunotherapeutics2023name in abstract: Convidecia
PMID 37553338Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.Nature communications2023name in title: Ad5-nCoV
PMID 37736100Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study.Frontiers in immunology2023name in title: Ad5-nCoV
PMID 37868993Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients.Frontiers in immunology2023name in title: Ad5-nCoV
PMID 34812213[Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine].Enfermedades infecciosas y microbiologia clinica2022name in title: Ad5-nCoV
PMID 34953526Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.Lancet (London, England)2022name in abstract: Ad5-nCoV
PMID 35087233Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.Nature medicine2022cited by trial NCT04892459
PMID 35277439Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.Neurology2022name in abstract: Ad5-nCoV
PMID 35605625Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.The Lancet. Respiratory medicine2022cited by trial NCT05043259
PMID 35617368Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.PLoS medicine2022cited by trial NCT04833101
PMID 35637121Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine.Enfermedades infecciosas y microbiologia clinica (English ed.)2022name in title: Ad5-nCoV
PMID 35943891Seizures following COVID-19 vaccination in Mexico: A nationwide observational study.Epilepsia2022name in abstract: Ad5-nCoV
PMID 35967368Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries.Frontiers in immunology2022name in abstract: Ad5-nCoV
PMID 36048417Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above.Expert review of vaccines2022cited by trial NCT05313646
PMID 34324836Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.The Lancet. Infectious diseases2021cited by trial NCT04552366
PMID 34622311Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.Rheumatology international2021name in abstract: Ad5-nCoV
PMID 32702299Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet (London, England)2020cited by trial NCT04341389

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 41555206Short-Term Change in IgG Antibody Elicited by Omicron BA.5 Infection and Inhaled Ad5-nCoV Vaccine Among Healthcare Workers.Immunity, inflammation and disease2026name in title: Ad5-nCoV
PMID 41640352Single-Cell Sequencing Reveals Varying Cell-Mediated Immunity Profiles in Individuals With Distinct Antibody Responses Following Ad5-nCoV Booster.The Journal of infectious diseases2026name in title: Ad5-nCoV
PMID 41847158A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants.Infectious Disease Modelling2026name in abstract: Ad5-nCoV
PMID 41913864Association Between COVID-19 Vaccination, Obesity, and Symptom Burden in a Mexican Population: A Retrospective Cross-Sectional Study.Cureus2026name in abstract: Ad5-nCoV
PMID 39786643Globally approved vaccines for COVID-19: a systematic review.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025name in abstract: Convidecia
PMID 39864283Screening for immunodominant epitopes of SARS-CoV-2 based on CD8+ T cell responses from individuals with HLA-A homozygous alleles.Molecular immunology2025name in abstract: Ad5-nCoV
PMID 40006661Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used.Vaccines2025name in abstract: Convidecia
PMID 40027891Safety and immunogenicity of Ad5-nCoV administered intradermally by needle-free injector in rats.Frontiers in medicine2025name in title: Ad5-nCoV
PMID 40036106Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis.The Indian journal of medical research2025name in abstract: Convidecia
PMID 40112804Molecular basis of Ad5-nCoV vaccine-induced immunogenicity.Structure (London, England : 1993)2025name in title: Ad5-nCoV
PMID 40177579Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants.Acta pharmaceutica Sinica. B2025name in abstract: Ad5-nCoV
PMID 40266233Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials.Vaccines2025name in abstract: Ad5-nCoV
PMID 40315818Cryo-ET unravels the mystery of Ad5-nCoV vaccines.Structure (London, England : 1993)2025name in title: Ad5-nCoV
PMID 41081494Kinetics of IgA Subtypes and Cytokines in Respiratory Secretions Following Immunization With COVID-19 Mucosal Vaccine.Journal of medical virology2025name in abstract: Ad5-nCoV
PMID 41113693Neutralization and Anti-S Antibody Titers in SARS-CoV-2 Boosted Adults in Mexico: A Comparison Across Five Vaccine Types.International journal of microbiology2025name in abstract: Ad5-nCoV
PMID 41183574Gut-initiated mucosal and systemic immunity against SARS-CoV-2 via an oral hyaluronic acid/chitosan vaccine coacervate.Journal of controlled release : official journal of the Controlled Release Society2025name in abstract: Ad5-nCoV
PMID 41462459Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell immunity.BMC medicine2025name in abstract: Ad5-nCoV
PMID 38250901A Potential Association between Abdominal Obesity and the Efficacy of Humoral Immunity Induced by COVID-19 and by the AZD1222, Convidecia, BNT162b2, Sputnik V, and CoronaVac Vaccines.Vaccines2024name in title: Convidecia
PMID 38296705Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.Vaccine2024name in abstract: Ad5-nCoV
PMID 38489915The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection.Virology2024name in abstract: Ad5-nCoV
PMID 38528666An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents.Recent patents on biotechnology2024name in abstract: Ad5-nCoV
PMID 38528839Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS-CoV-2 vaccine and Ad5-nCoV booster in pediatric liver transplant recipients.Journal of medical virology2024name in title: Ad5-nCoV
PMID 38543926Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial.Vaccines2024name in abstract: Ad5-nCoV
PMID 38547193Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico.PloS one2024name in abstract: Ad5-nCoV
PMID 38570727Comparative single-cell transcriptomic profile of hybrid immunity induced by adenovirus vector-based COVID-19 vaccines.Genes and immunity2024name in abstract: Ad5-nCoV
PMID 38573914Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.PloS one2024name in title: Ad5-nCoV
PMID 38629062Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein.Frontiers in immunology2024name in abstract: Ad5-nCoV
PMID 38650361Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.Journal of medical virology2024name in abstract: Ad5-nCoV
PMID 38932412Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6-17 Years: An Immunobridging Trial.Vaccines2024name in abstract: Ad5-nCoV
PMID 39178194A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV.Emerging microbes & infections2024name in title: Ad5-nCoV
PMID 39234239A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China.Frontiers in immunology2024name in abstract: Convidecia
PMID 39257586Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection.Frontiers in immunology2024name in abstract: Ad5-nCoV
PMID 39328415Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.Frontiers in immunology2024name in abstract: Ad5-nCoV
PMID 39360715Ad5-nCoV boosted vaccine and reinfection-induced memory T/B cell responses and humoral immunity to SARS-CoV-2: based on two prospective cohorts.Emerging microbes & infections2024name in title: Ad5-nCoV
PMID 39535117Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines.Human vaccines & immunotherapeutics2024name in title: Ad5-nCoV
PMID 39558654Erratum to "Evaluation of the Effectiveness and Safety of Sequential Vaccination With Inactivated SARS-CoV-2 Vaccine and Ad5-nCoV Booster in Pediatric Liver Transplant Recipients".Journal of medical virology2024name in title: Ad5-nCoV
PMID 39635888Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study.Viral immunology2024name in abstract: Convidecia
PMID 39695978Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China.BMC infectious diseases2024name in title: Ad5-nCoV
PMID 39835127Single-cell transcriptome atlas of peripheral immune features to Omicron breakthrough infection under booster vaccination strategies.Frontiers in immunology2024name in abstract: Ad5-nCoV
PMID 36127294Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.Journal of medical virology2023name in title: Ad5-nCoV
PMID 36602375Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population.Microbiology spectrum2023name in title: Convidecia
PMID 36603767Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees.Virologica Sinica2023name in abstract: Ad5-nCoV
PMID 36775188Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2023name in abstract: Ad5-nCoV
PMID 36922500Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine.Signal transduction and targeted therapy2023name in title: Ad5-nCoV
PMID 36998173Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.Human vaccines & immunotherapeutics2023name in abstract: Ad5-nCoV
PMID 37002983Comparison of the effectiveness of four SARS-COV-2 v accines in Nuevo Leon, Mexico: A test-negative control study.Atencion primaria2023name in abstract: Ad5-nCoV
PMID 37112754Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico.Vaccines2023name in abstract: Ad5-nCoV
PMID 37120638Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273.Signal transduction and targeted therapy2023name in title: Ad5-nCoV
PMID 37120945Handheld NIR-to-NIR Platform for on-site evaluating protective neutralizing antibody against SARS-CoV-2 ancestral strain and Omicron variant after vaccination or infection.Biosensors & bioelectronics2023name in abstract: Ad5-nCoV
PMID 37124338What contributes to the re-positive nucleic acid test results for the omicron variant of SARS-CoV-2 in the shelter cabin hospital in Shanghai, China?Heliyon2023name in abstract: Convidecia
PMID 37347197Two Novel Adenovirus Vectors Mediated Differential Antibody Responses via Interferon-α and Natural Killer Cells.Microbiology spectrum2023name in abstract: Ad5-nCoV
PMID 37400857Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.BMC medicine2023name in title: Ad5-nCoV
PMID 37501516A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov.Expert review of vaccines2023name in title: Ad5-nCoV
PMID 37615363SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico.Journal of medical virology2023name in abstract: Ad5-nCoV
PMID 37767190Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial.EClinicalMedicine2023name in abstract: Ad5-nCoV
PMID 37886231Assessing the real-world effectiveness of five SARS-CoV-2 vaccines in a cohort of Mexican pensioners: a nationwide nested test-negative design study.Lancet regional health. Americas2023name in abstract: Ad5-nCoV
PMID 38038866Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18-60 Years: a Single-Center, Open-Label Trial.Infectious diseases and therapy2023name in abstract: Ad5-nCoV
PMID 38140219The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.Vaccines2023name in title: Convidecia
PMID 38257752Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8+ T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.Viruses2023name in title: Ad5-nCoV
PMID 34755408Covid-19 vaccines and variants of concern: A review.Reviews in medical virology2022name in abstract: Ad5-nCoV
PMID 34918097Heterologous prime-boost strategies for COVID-19 vaccines.Journal of travel medicine2022name in abstract: Ad5-nCoV
PMID 35062750Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study.Vaccines2022name in abstract: Convidecia
PMID 35094672Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques.Emerging microbes & infections2022name in abstract: Ad5-nCoV
PMID 35153354[Reply: Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine].Enfermedades infecciosas y microbiologia clinica2022name in title: Ad5-nCoV
PMID 35206580Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.International journal of environmental research and public health2022name in abstract: Ad5-nCoV
PMID 35225871Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library.Antibodies (Basel, Switzerland)2022name in abstract: Convidecia
PMID 35335024Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers.Vaccines2022name in title: Ad5-nCoV
PMID 35335032Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.Vaccines2022name in title: Ad5-nCoV
PMID 35350457[Analysis of budgetary impact of COVID-19 vaccination in Latin AmericaAnálise do impacto orçamentário da vacinação contra a COVID-19 na América Latina].Revista panamericana de salud publica = Pan American journal of public health2022name in abstract: Convidecia
PMID 35359754Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population.Frontiers in public health2022name in abstract: Ad5-nCoV
PMID 35400561Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.Vaccine2022name in abstract: Convidecia
PMID 35478188Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.Signal transduction and targeted therapy2022name in abstract: Ad5-nCoV
PMID 35484064Reply: Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine.Enfermedades infecciosas y microbiologia clinica (English ed.)2022name in title: Ad5-nCoV
PMID 35604772mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.Emerging microbes & infections2022name in abstract: Ad5-nCoV
PMID 35749390Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico.PloS one2022name in title: Ad5-nCoV
PMID 35773445A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.Pharmaceutical research2022name in abstract: Ad5-nCoV
PMID 35787610Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination.Signal transduction and targeted therapy2022name in title: Ad5-nCoV
PMID 35813627Thyroid Inconveniences With Vaccination Against SARS-CoV-2: The Size of the Matter. A Systematic Review.Frontiers in endocrinology2022name in abstract: Convidecia
PMID 35818435Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.Acta pharmaceutica Sinica. B2022name in abstract: Ad5-nCoV
PMID 35841212Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.European journal of neurology2022name in abstract: Ad5-nCoV
PMID 35926505Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.Cell reports. Medicine2022name in title: Ad5-nCoV
PMID 35952506COVID-19 vaccination for patients with benign childhood epilepsy with centrotemporal spikes.Epilepsy & behavior : E&B2022name in abstract: Ad5-nCoV
PMID 35979461The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China.Frontiers in public health2022name in abstract: Ad5-nCoV
PMID 35987196SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors.Cell reports2022name in abstract: Ad5-nCoV
PMID 36016185Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2.Vaccines2022name in abstract: Ad5-nCoV
PMID 36028456Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients.Vaccine2022name in abstract: Ad5-nCoV
PMID 36049602Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.Clinical immunology (Orlando, Fla.)2022name in abstract: Ad5-nCoV
PMID 36105809Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.Frontiers in immunology2022name in abstract: Ad5-nCoV
PMID 36266697Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.BMC medicine2022name in title: Ad5-nCoV
PMID 36279685Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.Immunology letters2022name in title: Ad5-nCoV
PMID 36679869Effectiveness of COVID-19 Vaccines in Adults with Diabetes Mellitus: A Systematic Review.Vaccines2022name in abstract: Ad5-nCoV
PMID 33551672The COVID-19 puzzle: a global nightmare.Environment, development and sustainability2021name in abstract: Ad5-nCoV
PMID 33662986Development of SARS-CoV-2 vaccines.Boletin medico del Hospital Infantil de Mexico2021name in abstract: Ad5-nCoV
PMID 33761791A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.Journal of evidence-based integrative medicine2021name in abstract: Ad5-nCoV
PMID 33804914Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.Diagnostics (Basel, Switzerland)2021name in abstract: Ad5-nCoV
PMID 33807818SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.Vaccines2021name in abstract: Ad5-nCoV
PMID 34373443Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization.Cell discovery2021name in title: Ad5-nCoV
PMID 34579236IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population.Vaccines2021name in title: Ad5-nCoV
PMID 34579284Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.Vaccines2021name in title: Ad5-nCoV
PMID 34696209The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis.Vaccines2021name in abstract: Convidecia

Notes

Convidecia: single-dose recombinant Ad5 encoding the SARS-CoV-2 spike. Approved for limited military use in China on 25 June 2020 and for general use in February 2021; WHO emergency use listing May 2022; emergency authorisations in Mexico, Pakistan, Hungary, Chile, Malaysia, Indonesia and others not all listed here. The nebulised form Convidecia Air is the same construct given by oral inhalation, so it is a route rather than a new program (NMPA booster approval 4 September 2022); 'inhaled' is not a route value in the spec, so the route cell lists intramuscular only.

How to cite

Ad5-nCoV (AXP000169.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000169.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.